Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
Angelo Ruggiero, Vincenzo Picone, Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Naples, ItalyCorrespondence: Angelo Ruggiero, Section of Dermatology - Department of Clinical Medicine and Sur...
Saved in:
Main Authors: | Ruggiero A (Author), Picone V (Author), Martora F (Author), Fabbrocini G (Author), Megna M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
by: Martora F, et al.
Published: (2023) -
Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023) -
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
by: Megna M, et al.
Published: (2022) -
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
by: Potestio L, et al.
Published: (2023) -
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023)